Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes *Advertisement*
Phillip Home Send to Friends Free Subscription Give Comments 中文版
14 Jan, 2019 (Monday)


WUXI APPTEC(2359)
Analysis:
It is Asia`s largest pharmaceutical R&D service platform based on 2017 revenue, accounting for 1.1% of the global pharmaceutical R&D outsourcing service market. The market share is 8.3% in China. Focusing on the discovery, development and manufacturing of small molecule drugs. It also provides research and development and manufacturing services for cell and gene therapies, accounting for 8.1% and 18.2% of the global and US cell and gene therapy CMO/CDMO market share, respectively. It ranked fourth and second respectively. In the first half of this year, the revenue increased from RMB3.6billion to RMB4.4 billion, and the profit during the period increased from RMB786 million to RMB1.304 billion. GPM fell from 43.2% to 39.8% y.o.y, mainly due to the significant appreciation of the RMB against the US dollar. The return on equity in 2015, 2016, 2017 and the first half of this year were 12.07%, 17.95%, 20.26% and 30.55%, respectively. The global pharmaceutical market grew at a CAGR of 4.9% from 2013 to 3017 and is expected to grow at a CAGR of 5.7% by 2022. China is the second largest pharmaceutical market in the world. It is expected that the policy will continue to encourage the development of innovative patented drugs in the next five years. It is expected that the generic and patented drugs will grow at a CAGR of 8% by 2022. The cell and gene therapy CMO/CDMO grew at a CAGR of 23.2% from 2013 to 2017 and is expected to grow at a CAGR of 24.2% by 2022.
Strategy:
Buy-in Price: $67.55, Target Price: $78.00, Cut Loss Price: $64.00


Weichai (2338.HK) - Stable Advantage in Heavy Truck Industry Chain. Non-engine Business Gradually Takes off

Investment Summary

Net Profit in the First Three Quarters Hits a New High, Growth Rate Slows Down under a High Base

The Q3 revenue of Weichai Power in 2018 was down about 8.5% yoy to RMB35.92 billion, net profit attributable to the parent company down by 17.6% yoy to RMB1.91 billion, and the EPS stood at RMB0.2. The yoy decrease in Q3 was mainly due to the high base caused by the high prosperity of the heavy truck industry in the same period of the previous years, while the growth rate of the heavy truck industry slowed down significantly during the period.

In the first three quarters, the Company reported a revenue of RMB118.18 billion, up by 5.94% yoy, and a net profit attributable to the parent company of RMB6,001 million, up by 30.4% yoy, and the EPS stood at RMB0.75. Net profit of the Company in the first three quarters hit a record high since its listing.

Gross Margin Basically Stays Flat and Expenses Are Well Controlled

The Company's integrated gross margin in the first three quarters was 21.65%, basically staying flat and down by 0.04 ppts slightly, and the rise in the price of raw materials and the shift in product mix basically offset each other. The expenses of the Company were well controlled, the three rates were 12.92%, down approximately by 0.8 ppts over the same period last year, among which the sales expense rate was 6.7%, down by 0.32 ppts yoy, the administration expenses + R&D expenses rate were 6.17% (-0.05ppts yoy), and the financial expenses rate was 0.08% (-0.46ppts yoy).

The Company Has Stable Advantage in Heavy Truck Industry Chain. Non-engine Business Gradually Takes off

During the period, the Company's heavy-duty engine has been in a stronger position in heavy truck market, five-ton loader market and the market of passenger vehicles above 11 meters. In the first three quarters in 2018, the market share of the Company's heavy truck engine reached 30.2%, maintaining its leading position. We expect that the future heavy truck engine business of the Company will continue to benefit from the upward trend in the sales structure resulting from upgrading consumption in heavy truck industry.

Based on golden industry chains of heavy truck (engine + gearbox + axle + complete heavy truck), Weichai Power has steadily expanded its business scope since 2012, and laid out an industry chain featuring intelligent logistics solution through the acquisition of Baudouin, Linde Hydraulics, Kion and Dematic. In H1 of 2018, the sales revenue of Linde Hydraulics (China) doubled yoy, and the revenue of Kion in the Q3 stood at EUR1.9 billion (+3.5% yoy), the amount of order was EUR2.06 billion (+11.5%yoy) and net profit was EUR100 million (+21.8%yoy).

In addition, the proportion of the Company's non-road heavy truck engine has also been increased to about 30%, which is complementary and synergistic with the original business. The Company's "power + hydraulic" strategic framework is clear, which helps smooth the original business affected by periodic fluctuations of heavy truck industry, and the business structure is more balanced.

The Company Increases Input in New Energy Sector

After 2017, the Company has been keeping exploration in the field of new energy strategy and invested Ballard Power Systems in Canada, Foresight, Ceres Power in Britain, PSI in the US, and the Company also increased input in R&D to enter the new energy field of fuel cells. At present, the Company has taken control of high-quality resources, such as hydrogen fuel cells and solid oxide fuel cells in new energy business. In future, the Company will strengthen R&D in core technology and accelerate the implementation of new energy business.

Investment Thesis

We believe that although the high prosperity of heavy truck industry is unlikely to continue, factors such as stricter environmental protection policies, upgrading of emission standard, overload control and rapid development of e-commerce logistics will support the stable sales of heavy truck in China. The chairman of the Company also serves as the chairman of Sinotruk, and it is expected that Sinotruk will increase engine purchasing volume of the company in the future. We reaffirm the "Accumulate" rating with the target price to HKD 10.65, equivalent to 9.9/9.8x P/E ratio in2018/2019. (Closing price as at 10 January 2019)

Financials

Click Here for PDF format...




Recommendation on 14-1-2019
RecommendationAccumulate
Price on Recommendation Date$ 8.960
Suggested purchase priceN/A
Target Price$ 10.650
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+86 21 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2019 Phillip Securities (HK) Ltd. All Rights Reserved.